Role of Bevacizumab in Uterine Leiomyosarcoma

In the recent years, angiogenetic inhibitors have emerged for the treatment of several malignancies. In particular, bevacizumab has proved to be effective in many types of cancers (including sarcoma), but the limitations of antiangiogenic therapy have been shown in practice. Here, we sought to review the current evidence on the role and efficacy of bevacizumab in patients affected by uterine leiomyosarcoma. On April 2017, Literature was searched in order to identify studies reporting outcomes of patients affected either by early stage or advanced/recurred uterine leiomyosarcoma undergoing treatment with bevacizumab, alone or in combination with other chemotherapeutic regimens.

Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Giorgio Bogani, Antonino Ditto, Fabio Martineli, Mauro Signorelli, Valentina Chiappa, Caterina Fonatella, Roberta Sanfilippo, Umberto Leone Roberti Maggiore, Simone Ferrero, Domenica Lorusso, Francesco Raspagliesi Source Type: research